The U.S. Food and Drug Administration (U.S FDA) has approved Natco Pharma’s abbreviated new drug application (ANDA) for cancer drug Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) single-dose vials, the generic drugmaker and its alliance partner Lupin said on Wednesday (June 3, 2026).

The approved product is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai Inc. The RLD (Halaven) had an estimated annual sales of $43.7 million in the U.S., the two companies said citing IQVIA MAT April 2026 numbers. Eribulin Mesylate injection is indicated for the treatment of adults with metastatic breast cancer.